Cupric Chloride Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Cupric Chloride Injection Supply Disruption

Cupric Chloride Injection (0.4 mg/mL, Hospira/Pfizer) — the single-ingredient IV copper supplement used in total parenteral nutrition (TPN) — continues to face intermittent supply constraints in 2026. For providers managing patients on parenteral nutrition, this shortage has direct implications for prescribing, monitoring, and clinical outcomes.

This article provides an evidence-based overview of the current shortage landscape, prescribing considerations, alternative products, and clinical tools to help you navigate this ongoing challenge.

Shortage Timeline and Current Status

Parenteral trace element shortages have been a recurring problem in the U.S. since the early 2010s. Individual trace element injections — including copper, zinc, chromium, manganese, and selenium — have appeared on the ASHP Drug Shortages List multiple times over the past decade.

Key milestones:

• 2012-2015: Widespread trace element shortages documented, including published case reports of copper and zinc deficiency in TPN patients during supply gaps
• 2020: FDA approval of Tralement (American Regent) — the first FDA-approved multi-trace element injection — partially addressing supply concerns
• 2022: FDA approved a new ANDA for Cupric Chloride Injection (ANDA 212071), potentially expanding the generic manufacturer base
• 2024-2026: Intermittent availability continues. Hospira/Pfizer remains the primary single-ingredient copper supplier. Allocation limits reported by some distributors

Prescribing Implications

When Cupric Chloride supply is disrupted, providers should address several clinical considerations:

Copper Deficiency Risk

Patients on long-term PN without adequate copper supplementation are at risk for clinically significant deficiency. The literature documents:

• Hematologic manifestations: Anemia (often refractory to iron), neutropenia, and leukopenia — typically appearing within 4-12 weeks of copper depletion
• Neurologic manifestations: Myelopathy, peripheral neuropathy, and optic neuropathy — which may only stabilize (not fully reverse) with copper repletion
• Other effects: Depressed ceruloplasmin levels, impaired transferrin formation, secondary iron deficiency, osteoporosis

Monitoring Protocol During Shortage

The prescribing information recommends serum copper and ceruloplasmin assays twice monthly for long-term TPN patients. During periods of supply disruption, consider increasing monitoring frequency, especially when:

• Transitioning between copper products (e.g., from Cupric Chloride to Tralement)
• Any gap in copper supplementation exceeds 1-2 weeks
• Patient develops unexplained cytopenias, anemia, or neurological symptoms

Dose Adjustments

Standard adult dosing for Cupric Chloride is 0.5-1.5 mg elemental copper per day. When substituting alternative products:

• Tralement: Contains 0.3 mg copper/mL. Standard adult dose is 1 mL/day, providing 0.3 mg copper — at the lower end of the recommended range. Consider whether supplemental copper is needed for patients with higher requirements.
• Cupric Sulfate Injection: Equivalent elemental copper dosing; verify concentration and adjust volume accordingly.

Current Availability Picture

The availability landscape for parenteral copper in 2026:

• Cupric Chloride Injection 0.4 mg/mL (Hospira/Pfizer): Available but intermittently allocated. NDC 0409-4092-01 (tray of 25 x 10 mL vials). Contact Pfizer Medical Information (1-800-438-1985) for real-time supply status.
• Tralement (American Regent): Multi-trace element injection (zinc 3 mg, copper 0.3 mg, manganese 55 mcg, selenium 60 mcg per mL). FDA-approved for patients ≥10 kg. Available through standard wholesale channels.
• Cupric Sulfate Injection: Alternative copper salt formulation available from select manufacturers.
• 503B Compounded Copper Solutions: FDA-registered outsourcing facilities may compound sterile copper solutions when commercial products are unavailable. Verify facility registration and quality standards.

Medfinder for Providers can help your clinical team track real-time availability of Cupric Chloride and alternatives across pharmacies and distributors.

Cost and Access Considerations

Cupric Chloride Injection is a relatively low-cost component of TPN (approximately $22 per 10 mL vial, or $558 per tray of 25 vials), but the cost to patients is typically bundled into their overall parenteral nutrition supply charges.

Access barriers during shortages include:

• Distributor allocation limits — pharmacies may be restricted to ordering limited quantities
• Geographic variation — supply may be available in some regions but not others
• Insurance formulary issues — switching to Tralement may require formulary adjustments or prior authorization updates
• Home infusion logistics — patients receiving PN at home depend on their infusion company to source all TPN components; trace element shortages can delay TPN compounding

For patients facing financial barriers, see our patient-facing resource: How to Save Money on Cupric Chloride in 2026.

Tools and Resources for Providers

• Medfinder for Providers — real-time medication availability tracking, including trace elements
• ASHP Drug Shortages List — official shortage tracking with manufacturer updates and estimated resolution dates
• FDA Drug Shortage Database — federal-level shortage reporting and manufacturer communications
• Pfizer Medical Information — 1-800-438-1985 for product-specific availability inquiries
• American Regent — for Tralement supply and clinical information: artraceelements.com

Looking Ahead

The structural factors driving trace element shortages — limited manufacturer base, complex sterile manufacturing, thin margins, and fragile supply chains — are unlikely to resolve quickly. However, several positive developments are underway:

• Additional ANDA approvals may bring new Cupric Chloride manufacturers to market
• Tralement provides a reliable multi-element alternative that didn't exist before 2020
• FDA and Congress continue to prioritize drug shortage prevention through reporting requirements and manufacturing quality incentives
• 503B outsourcing facilities provide a safety valve during acute shortages

Providers should maintain contingency plans for trace element substitution and ensure monitoring protocols are in place for all patients on long-term parenteral nutrition.

Final Thoughts

Copper is a trace element — but copper deficiency is not a trace problem. The hematologic and neurologic consequences of untreated deficiency are significant and sometimes irreversible. Maintaining vigilance around copper supplementation during this shortage, using available alternatives, and monitoring patient labs are the best defenses against adverse outcomes.

For clinical guidance on helping your patients navigate availability challenges, see our companion guide: How to Help Your Patients Find Cupric Chloride in Stock: A Provider's Guide.